Amyloidosis Treatment Market – Industry Analysis Report till 2025

The global Amyloidosis Treatment Market size is expected to reach USD 6.7 billion by 2025, according to a new report by Grand View Research, Inc., registering a 7.2% CAGR during the forecast period. Several factors such as increased adoption of novel targeted therapies and transplantations, emergence of biologics, and rising geriatric population are driving the market.

Amyloidosis is a group of rare diseases where misfolded aggregates of proteins (amyloids) buildup in tissues and organs. AL amyloidosis is the most common type of amyloidosis in U.S., with approximately 3,000 to 4,000 new cases diagnosed annually. Although in majority of cases, the disease is diagnosed in people over the age of 60, there are a few cases of people being diagnosed in their late 20s and about two-thirds of the patients are male.

Among treatments, chemotherapy held the largest share in 2017, followed by targeted therapy, and supportive care. However, targeted therapies are expected to dominate the market in 2025, supported by a strong pipeline and potential approval of drugs such as Alnylam’s Onpattro, Ionis’ Tegsedi, Johnson & Johnson’s Darzalex, and Takeda’s Ninlaro.

Stem cell transplants and targeted therapies are gaining traction in developed countries. However, amyloidosis cohorts in endemic regions do not have access to sufficient healthcare infrastructure to ensure prompt diagnosis and treatment in underdeveloped countries. Chemotherapy and supportive care are anticipated to lose market share over the forecast period due to adverse side effects and lower efficacy.

Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/amyloidosis-treatment-market

Further key findings from the report suggest:

• An estimated 16,000 people in U.S. suffer from amyloidosis, with approximately 3,000 to 4,000 new cases being reported annually
• U.S. dominated the global amyloidosis treatment market, with a share of more than 27.0% in 2017 due to potential launch of pipeline drugs, increased adoption of novel therapeutics, and high cost of treatment in the country
• Chemotherapy dominated the amyloidosis treatment market, with a share of about 35.0% in 2017. Targeted therapies are projected to witness double-digit growth during the forecast period due to multiple product approvals
• Emerging markets for amyloidosis such as China, Sweden, Portugal, Turkey, South Africa, Brazil, Mexico, Saudi Arabia, and India are expected to show attractive growth over the forecast period due to improved healthcare infrastructure, favorable government policies, increased investment, and large amyloidosis cohort
• Alnylam, Ionis, Pfizer, Johnson & Johnson and Takeda are some of the key players operating in this market
• Currently, 19 products are under evaluation for amyloidosis treatment in various stages of clinical development. Promising pipeline candidates such as Onpattro, Vyndaqel, Tegsedi, Darzalex, and Ninlaro are expected to generate significant revenue upon launch.

 About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com